Kyowa Kirin Co., Ltd. (FRA:KY4)

Market Cap	6.90B
Revenue (ttm)	2.91B
Net Income (ttm)	226.71M
Shares Out	n/a
EPS (ttm)	0.43
PE Ratio	30.46
Forward PE	n/a
Dividend	0.35 (2.68%)
Ex-Dividend Date	Jun 27, 2025

Volume	n/a
Average Volume	163
Open	13.10
Previous Close	13.20
Day's Range	13.00 - 13.10
52-Week Range	12.30 - 16.30
Beta	n/a
RSI	25.72
Earnings Date	Oct 30, 2025

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, sells, and import/export of pharmaceuticals products worldwide. It’s pipeline consist of OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4083/AMG 45, which is in Phase III and II clinical trial for the treatment of atopic dermatitis and prurigo nodularis, and asthma; OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A; ziftomenib, which is in Phase II and I clinical trial for the treatment of...

• Industry: Pharmaceutical Preparations
• Founded: 1949
• Employees: 5,669
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KY4

Financial Performance

In 2024, Kyowa Kirin's revenue was 495.56 billion, an increase of 12.06% compared to the previous year's 442.23 billion. Earnings were 59.87 billion, a decrease of -26.26%.

Financial numbers in JPY